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β-lactam antibiotics are the most
commonly prescribed antimicrobials. This
class of antibiotics includes penicillin,
cephalosporin, and carbapenem. In these
drugs, there is a strained four membered
ring with an amide bond known as
a β-lactam ring that is important for
the reactivity of β-lactams. β-lactam
antibiotics act by inhibiting penicillin
binding proteins (PBPs), an enzyme native
to bacteria, and disrupt biosynthesis of
the bacterial cell wall leading to cell lysis
and death. Unfortunately, bacteria have
developed mechanisms that eliminate the
β-lactam’s potency, subsequently leading
to resistance.
Among the mechanisms bacteria
employ for resistance, the expression of
β-lactamases is the most common. These
enzymes confer resistance to β-lactam
antibiotics by hydrolyzing the lactam ring
through a two-step acylation-deacylation
mechanism. Once the β-lactam ring is
hydrolyzed, it is inactivated. There are
four classes of β-lactamases: A, B, C,
and D. Classes A, C, and D employ a
serine based mechanism to hydrolyze the
β-lactam ring, while class B β-lactamases
are metalloproteins that require zinc
for their activity. Although all classes of
β-lactamases are of clinical importance,
class D β-lactamases, also known as
OXAs, are the least understood. A
particular subset of the class D enzymes
is of particular concern: the carbapenemhydrolyzing class D β-lactamases of
which OXA-24 is a member. In OXA-24
mechanism, a carboxylated lysine is used
to hydrolyze carbapenems, which is a
troubling trend, as carbapenems are the
newest antibiotics and often used as a last
resort.
In an effort to combat antibiotic
resistance against β-lactams, combination
therapies consisting of a β-lactam
antibiotic with a β-lactamase inhibitor
have been employed. However, current
β-lactamase inhibitors also contain a
β-lactam ring. Due to this structural
similarity to β-lactam antibiotics,
inhibitors are also susceptible to existing
resistance mechanisms of bacteria.

Currently, there are no commercially
available inhibitors for class D
β-lactamases. The main objective of our
research is studying class D β-lactamases
to discover novel inhibitors that are
structurally different from β-lactam
antibiotics. In this effort, creating novel
inhibitors would serve as an advantage
against bacteria by circumventing
the traditional β-lactam resistance
mechanisms.
To discover a novel inhibitor for
OXA-24, we took a structure-based
approach to optimize an identified lead
fragment. In the beginning stages, a
molecular docking program, DOCK,
identified a non-covalent fragment
(Fragment #5) showing some signs of
inhibition against OXA-24 with a Ki
of 3.53 mM. For optimizing this lead,
commercially available analogs were
ordered and tested for inhibition against
OXA-24. So far, nine analog compounds
have been experimentally tested against
OXA-24. Of the nine analogs, one
inhibits with a Ki of 0.100 mM, showing
improved binding affinity of 35 fold
over the lead. As a continuing focus, we
will look at further optimizing this series
of novel inhibitors to improve binding,
ultimately working towards developing a
clinically-relevant novel inhibitor.

